Clinical Significance of HER2-low Breast Cancer

被引：0
|
作者：
Zaiem, Fadi
AbuJamea, Asem
Kheil, Mira
Numi, Anna
Abbas, Omar
Awada, Sanaa
Almsaddi, Ragad
Al-Juburi, Saleh
Larson, Lauren
Jain, Deepti
AlSaghir, Maya
Jang, Hyejeong
Kim, Seongho
Bandyopadhyay, Sudeshna
Jaiman, Sunil
Ali-Fehmi, Rouba
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-01-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-01-11
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clinicopathological features and prognostic significance of HER2-low status in breast carcinoma
    Ilieva-Shipchanova, N.
    Tashkova, D.
    Bangieva, E.
    Miteva, N.
    VIRCHOWS ARCHIV, 2024, 485 : S194 - S194
  • [42] Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
    Lei-Jie Dai
    Ding Ma
    Yu-Zheng Xu
    Ming Li
    Yu-Wei Li
    Yi Xiao
    Xi Jin
    Song-Yang Wu
    Ya-Xin Zhao
    Han Wang
    Wen-Tao Yang
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Communications, 14
  • [43] The " lows " : Update on ER-low and HER2-low breast cancer
    Fusco, Nicola
    Viale, Giuseppe
    BREAST, 2024, 78
  • [44] Clinical characteristics of HER2-low stage I triple-negative breast cancer
    Sanomachi, Tomomi
    Shumiyoshi, Hitomi Okuma
    Kitadai, Rui
    Kawachi, Asuka
    Yazaki, Shu
    Tokura, Momoko
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Suto, Akihiko
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1401 - S1401
  • [45] Her2-Low Breast Cancer: Incidence, Clinical, Pathological Characteristics, and Oncotype Dx Scores
    Zhang, Gloria
    Van Arnam, John
    Cui, Xiaoyan
    Lewis, Gloria
    McIntire, Patrick
    Hoda, Raza
    Fong, Nancy
    Booth, Christine
    Rowe, J. Jordi
    Hashem, Sherin
    Sciallis, Andrew
    Kruse, Megan
    LABORATORY INVESTIGATION, 2023, 103 (03) : S241 - S242
  • [46] Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
    Dai, Lei-Jie
    Ma, Ding
    Xu, Yu-Zheng
    Li, Ming
    Li, Yu-Wei
    Xiao, Yi
    Jin, Xi
    Wu, Song-Yang
    Zhao, Ya-Xin
    Wang, Han
    Yang, Wen-Tao
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [47] Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
    Mengdi Chen
    Weilin Chen
    Deyue Liu
    Weiguo Chen
    Kunwei Shen
    Jiayi Wu
    Li Zhu
    Breast Cancer, 2022, 29 : 844 - 853
  • [48] Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
    Jin, Juan
    Li, Bin
    Cao, Jianing
    Li, Ting
    Zhang, Jian
    Cao, Jun
    Zhao, Mingchuan
    Wang, Leiping
    Wang, Biyun
    Tao, Zhonghua
    Hu, Xichun
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [49] Evaluation of HER2 scoring algorithms for identification of HER2-low breast cancer
    Costache, S.
    Nagy, A.
    Billingham, K.
    Haynes, H.
    Chefani, A.
    Thomas, T.
    Wedden, S.
    D'Arrigo, C.
    VIRCHOWS ARCHIV, 2020, 477 : S222 - S223
  • [50] Defining the patient population with HER2-low breast cancer in Hawaii
    Beaman, Amanda Yachiyo
    Hayama, Sara
    Pagano, Ian
    Killeen, Jeffrey
    Fukui, Jami Aya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345